4-chloro-1-(2-hydroxyphenyl)-1-butanone | 313369-21-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-chloro-1-(2-hydroxyphenyl)-1-butanone
• 英文别名: 4-chloro-1-(2-hydroxyphenyl)butan-1-one
• CAS: 313369-21-0
• 化学式: C₁₀H₁₁ClO₂
• 分子量: 198.649
• InChiKey: OXJZITPMUHPEQJ-UHFFFAOYSA-N

物化性质

• 沸点：
  317.6±22.0 °C(Predicted)
• 密度：
  1.212±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-哌嗪-1,2-苯异唑 、 4-chloro-1-(2-hydroxyphenyl)-1-butanone 以 乙腈 为溶剂， 以27%的产率得到4-(4-Benzo[d]isoxazol-3-yl-piperazin-1-yl)-1-(2-hydroxy-phenyl)-butan-1-one
  参考文献：
  名称：

  Synthesis and Structure−Affinity Relationships of 1-[ω-(4-Aryl-1-piperazinyl)alkyl]-1-aryl Ketones as 5-HT₇ Receptor Ligands

  摘要：

  Structural requirements for 5-HT7 receptor affinity and selectivity over that for the 5-HT1A receptor were studied on a series of 1-[omega-(4-aryl-1-piperazinyl)alkyl] - I-aryl ketones. The presence of a hydroxy or methoxy substituent on aryl ketone moiety, alkyl chain length, and the nature of N-1-piperazine substituent were explored. 6-[4-(3-Benzisoxazolyl)-l-piperazinyl]-1-(2-hydroxyphenyl)-1-hexanone (40) and its methoxy analogue 43 exhibited high 5-HT7 receptor affinities (K-i = 2.93 nM and 0.90 nM, respectively) and agonist properties when tested for 5-HT7 receptor-mediated relaxation of substance P-induced guinea-pig ileum contraction.

  DOI：

  10.1021/jm020994z
• 作为产物：
  描述：

  2-(2-methyloxyphenyl)-2-(trimethylsilyloxy)acetonitrile 在 正丁基锂 、 氢溴酸 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 反应 6.5h， 生成 4-chloro-1-(2-hydroxyphenyl)-1-butanone
  参考文献：
  名称：

  Synthesis and Structure−Affinity Relationships of 1-[ω-(4-Aryl-1-piperazinyl)alkyl]-1-aryl Ketones as 5-HT₇ Receptor Ligands

  摘要：

  Structural requirements for 5-HT7 receptor affinity and selectivity over that for the 5-HT1A receptor were studied on a series of 1-[omega-(4-aryl-1-piperazinyl)alkyl] - I-aryl ketones. The presence of a hydroxy or methoxy substituent on aryl ketone moiety, alkyl chain length, and the nature of N-1-piperazine substituent were explored. 6-[4-(3-Benzisoxazolyl)-l-piperazinyl]-1-(2-hydroxyphenyl)-1-hexanone (40) and its methoxy analogue 43 exhibited high 5-HT7 receptor affinities (K-i = 2.93 nM and 0.90 nM, respectively) and agonist properties when tested for 5-HT7 receptor-mediated relaxation of substance P-induced guinea-pig ileum contraction.

  DOI：

  10.1021/jm020994z

文献信息

• Substituted heterocycle fused gamma-carbolines
  申请人：——

  公开号：US20040220178A1

  公开（公告）日：2004-11-04

  The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) 1 or pharmaceutically acceptable salt forms thereof, wherein R 1 , R 5 , R 6a , R 6b , R 7 , R 8 , R 9 , X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

  本发明涉及通过给予由结构式（I）表示的化合物或其药学上可接受的盐形式来治疗成瘾行为和睡眠障碍的方法，其中R1、R5、R6a、R6b、R7、R8、R9、X、b、k、m和n以及虚线如本文所述。本发明治疗方法中使用的化合物是5-羟色胺激动剂和拮抗剂，对于控制或预防包括成瘾行为和睡眠障碍在内的中枢神经系统疾病是有用的。
• Substituted heterocycle fused γ-carbolines
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：US07183282B2

  公开（公告）日：2007-02-27

  The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

  本发明涉及用于治疗成瘾行为和睡眠障碍的化合物，其结构式表示为（I）或其药学上可接受的盐形式，其中R1、R5、R6a、R6b、R7、R8、R9、X、b、k、m和n以及虚线如本文所述。本发明治疗方法中使用的化合物是5-羟色胺激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括成瘾行为和睡眠障碍。
• USRE039680E1
  申请人：——

  公开号：——

  公开（公告）日：——
• USRE039679E1
  申请人：——

  公开号：——

  公开（公告）日：——
• SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1189904B1

  公开（公告）日：2004-09-22